NO20054405L - Kjemokinreseptor-binende heterosykel - Google Patents
Kjemokinreseptor-binende heterosykelInfo
- Publication number
- NO20054405L NO20054405L NO20054405A NO20054405A NO20054405L NO 20054405 L NO20054405 L NO 20054405L NO 20054405 A NO20054405 A NO 20054405A NO 20054405 A NO20054405 A NO 20054405A NO 20054405 L NO20054405 L NO 20054405L
- Authority
- NO
- Norway
- Prior art keywords
- heterocycle
- binding
- chemokine receptor
- compounds
- useful
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title 1
- 108050000299 Chemokine receptor Proteins 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 108010061299 CXCR4 Receptors Proteins 0.000 abstract 1
- 102000012000 CXCR4 Receptors Human genes 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 238000004820 blood count Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46485803P | 2003-04-22 | 2003-04-22 | |
| US50523003P | 2003-09-22 | 2003-09-22 | |
| PCT/US2004/012627 WO2004093817A2 (en) | 2003-04-22 | 2004-04-22 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054405D0 NO20054405D0 (no) | 2005-09-22 |
| NO20054405L true NO20054405L (no) | 2006-01-19 |
Family
ID=33313500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054405A NO20054405L (no) | 2003-04-22 | 2005-09-22 | Kjemokinreseptor-binende heterosykel |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7550484B2 (enExample) |
| EP (2) | EP1615633B1 (enExample) |
| JP (1) | JP4778420B2 (enExample) |
| KR (1) | KR20050115455A (enExample) |
| CN (1) | CN101941964A (enExample) |
| AU (1) | AU2004232361A1 (enExample) |
| BR (1) | BRPI0409655B8 (enExample) |
| CA (1) | CA2517077C (enExample) |
| ES (1) | ES2393188T3 (enExample) |
| IL (1) | IL170207A (enExample) |
| IN (1) | IN266744B (enExample) |
| MX (1) | MXPA05011353A (enExample) |
| NO (1) | NO20054405L (enExample) |
| NZ (1) | NZ542850A (enExample) |
| RU (1) | RU2005136224A (enExample) |
| WO (1) | WO2004093817A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2005136224A (ru) * | 2003-04-22 | 2006-06-10 | Анормед Инк. (Ca) | Гетероциклические соединения, связывающиеся с рецепторами хемокинов и обладающие повышенной эффективностью |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| JP2008509928A (ja) * | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
| AU2006203826A1 (en) | 2005-01-07 | 2006-07-13 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| WO2007025166A2 (en) * | 2005-08-25 | 2007-03-01 | Repair Technologies, Inc. | Devices, compositions and methods for the protection and repair of cells and tissues |
| WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| JP2009545620A (ja) * | 2006-08-02 | 2009-12-24 | ジェンザイム・コーポレーション | 併用療法 |
| MX2009001445A (es) * | 2006-08-07 | 2009-02-18 | Genzyme Corp | Terapia de combinacion. |
| KR20110005819A (ko) | 2008-03-28 | 2011-01-19 | 알티리스 쎄라퓨틱스 | 케모카인 수용체 조절제 |
| CN103275071B (zh) * | 2013-05-17 | 2015-04-15 | 山西大学 | 一种香豆素衍生物及其制备方法和用途 |
| WO2015187663A1 (en) * | 2014-06-02 | 2015-12-10 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of hiv-2 infection |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| EP3808748B1 (en) | 2016-06-21 | 2026-05-20 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020264292A1 (en) * | 2019-06-26 | 2020-12-30 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN115515585A (zh) | 2020-03-10 | 2022-12-23 | X4 制药有限公司 | 用于治疗中性粒细胞减少症的方法 |
| WO2025224720A1 (en) | 2024-04-24 | 2025-10-30 | Biolinerx Ltd. | Methods of selecting treatment regimen against solid tumors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5235056A (en) | 1992-04-22 | 1993-08-10 | Ciba-Geigy Corporation | Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| IL145401A0 (en) | 1999-03-24 | 2002-06-30 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| CN1185232C (zh) * | 1999-10-20 | 2005-01-19 | 田边制药株式会社 | αLβ2介导细胞粘连抑制剂 |
| DE60103052T2 (de) * | 2000-05-09 | 2005-03-03 | The University Of British Columbia, Vancouver | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten |
| KR20030034184A (ko) | 2000-09-15 | 2003-05-01 | 아노르메드 인코포레이티드 | 케모킨 수용체 결합 헤테로사이클릭 화합물 |
| RU2289581C2 (ru) | 2000-09-15 | 2006-12-20 | Анормед, Инк. | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение |
| NZ524421A (en) | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| GB0030673D0 (en) * | 2000-12-15 | 2001-01-31 | Unilever Plc | Ligand and complex for catalytically bleaching a substrate |
| JP2002284779A (ja) * | 2001-01-18 | 2002-10-03 | Sankyo Co Ltd | ヘテロアリール置換ピロール誘導体を含有する医薬 |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| US7491544B2 (en) * | 2002-05-20 | 2009-02-17 | New York University | Chiral piperidine and quinucledine ligands |
| RU2005136224A (ru) * | 2003-04-22 | 2006-06-10 | Анормед Инк. (Ca) | Гетероциклические соединения, связывающиеся с рецепторами хемокинов и обладающие повышенной эффективностью |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| US10468384B2 (en) | 2017-09-15 | 2019-11-05 | STATS ChipPAC Pte. Ltd. | Semiconductor device and method of forming embedded die substrate, and system-in-package modules with the same |
-
2004
- 2004-04-22 RU RU2005136224/04A patent/RU2005136224A/ru not_active Application Discontinuation
- 2004-04-22 NZ NZ542850A patent/NZ542850A/en unknown
- 2004-04-22 EP EP04760161A patent/EP1615633B1/en not_active Expired - Lifetime
- 2004-04-22 AU AU2004232361A patent/AU2004232361A1/en not_active Abandoned
- 2004-04-22 EP EP11160853A patent/EP2374804A1/en not_active Withdrawn
- 2004-04-22 JP JP2006513270A patent/JP4778420B2/ja not_active Expired - Lifetime
- 2004-04-22 CA CA2517077A patent/CA2517077C/en not_active Expired - Lifetime
- 2004-04-22 IN IN2076KON2005 patent/IN266744B/en unknown
- 2004-04-22 KR KR1020057020099A patent/KR20050115455A/ko not_active Withdrawn
- 2004-04-22 CN CN2010102549975A patent/CN101941964A/zh active Pending
- 2004-04-22 WO PCT/US2004/012627 patent/WO2004093817A2/en not_active Ceased
- 2004-04-22 BR BRPI0409655A patent/BRPI0409655B8/pt not_active IP Right Cessation
- 2004-04-22 MX MXPA05011353A patent/MXPA05011353A/es active IP Right Grant
- 2004-04-22 US US10/831,098 patent/US7550484B2/en not_active Expired - Lifetime
- 2004-04-22 ES ES04760161T patent/ES2393188T3/es not_active Expired - Lifetime
-
2005
- 2005-08-10 IL IL170207A patent/IL170207A/en active IP Right Grant
- 2005-09-22 NO NO20054405A patent/NO20054405L/no not_active Application Discontinuation
-
2009
- 2009-05-15 US US12/467,006 patent/US20090281308A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0409655A (pt) | 2006-04-18 |
| JP2006524700A (ja) | 2006-11-02 |
| WO2004093817A3 (en) | 2005-04-28 |
| ES2393188T3 (es) | 2012-12-19 |
| BRPI0409655B1 (pt) | 2019-12-03 |
| AU2004232361A1 (en) | 2004-11-04 |
| EP1615633A2 (en) | 2006-01-18 |
| CA2517077A1 (en) | 2004-11-04 |
| KR20050115455A (ko) | 2005-12-07 |
| IN266744B (enExample) | 2015-05-29 |
| EP1615633B1 (en) | 2012-08-15 |
| BRPI0409655B8 (pt) | 2021-05-25 |
| US20050059702A1 (en) | 2005-03-17 |
| WO2004093817A2 (en) | 2004-11-04 |
| EP1615633A4 (en) | 2008-07-09 |
| NO20054405D0 (no) | 2005-09-22 |
| HK1089930A1 (en) | 2006-12-15 |
| JP4778420B2 (ja) | 2011-09-21 |
| CA2517077C (en) | 2013-03-12 |
| RU2005136224A (ru) | 2006-06-10 |
| NZ542850A (en) | 2007-12-21 |
| IL170207A (en) | 2011-06-30 |
| US7550484B2 (en) | 2009-06-23 |
| MXPA05011353A (es) | 2005-11-28 |
| EP2374804A1 (en) | 2011-10-12 |
| US20090281308A1 (en) | 2009-11-12 |
| CN101941964A (zh) | 2011-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN266744B (enExample) | ||
| ECSP088324A (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas | |
| SG150550A1 (en) | Pharmaceutical preparation containing an antibody for the egf receptor | |
| WO2006074426A3 (en) | Cxcr4 antagonists for the treatment of hiv infection | |
| BR112012015576A2 (pt) | "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso" | |
| NO20080913L (no) | HIV-revers-transriptaseinhibitorer | |
| NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
| NO20082414L (no) | Inhibitorer av AKT-aktivitet | |
| UA86599C2 (en) | Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides | |
| CR8891A (es) | Antagonismo de la actividad del receptor de interleuquina 21 | |
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| NO20073765L (no) | Forbindelser for behandling av flaviviridae | |
| DE60042828D1 (de) | Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion | |
| NO20064547L (no) | Fremgangsmater for behandling av HIV infeksjon | |
| SE0202598D0 (sv) | Alpha-7 Nicotinic receptor agonists and statins in combination | |
| AR039460A1 (es) | Factores camp quimericos | |
| ATE534652T1 (de) | Phosphono-pent-2-en-1-yl-nukleoside und analoga | |
| MX2024010673A (es) | Compuestos antivirales y metodos de elaboracion y uso de los mismos. | |
| NO20074780L (no) | Heterocyklylamidsubstituerte imidazoler | |
| ATE434614T1 (de) | 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer | |
| MX2026002369A (es) | Compuestos antivirales y metodos de elaboracion y uso de los mismos | |
| TW200716110A (en) | Inhibitors of AKT activity | |
| NO20014890L (no) | Fremgangsmåte for behandling av schizofreni | |
| NO20082838L (no) | 9-klor-15-deoksyprostaglandinderivater, fremgangsmate for fremstilling av disse, og anvendelse som medikamenter | |
| NO20065151L (no) | Piperazinylpiperidinderivater som cytokin reseptor antagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |